We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Hemogenyx Pharmaceuticals Plc | LSE:HEMO | London | Ordinary Share | GB00BYX3WZ24 | ORD GBP0.01 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.014 | 0.87% | 1.629 | 1.62 | 1.638 | 1.70 | 1.614 | 1.61 | 4,149,071 | 16:35:20 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Finance Services | 0 | -3.98M | -0.0035 | -4.69 | 18.73M |
Date | Subject | Author | Discuss |
---|---|---|---|
23/4/2024 09:08 | looking for a move to 2.5-4p an explosive move on good news the science continues.. | purple11 | |
23/4/2024 08:29 | How's your 2.3p PPP shares doing purple11?.....LOL Simples!.......;-) | nigoil | |
23/4/2024 08:01 | 122856 my BUY@1.615 Will add twice more higher or lower gl | purple11 | |
22/4/2024 22:47 | hemo often pushes the price up to 4p on good news i expect another go 2 1/2p a nice trade for a thousand buying at 1.5p always pays off in hemo | purple11 | |
22/4/2024 22:29 | yes i will ofcourse | purple11 | |
22/4/2024 22:23 | Being so candid, Purple, I assume you'll be posting your 'Buy' on here when you do tomorrow. When you don't, please expect nothing less than what you deserve... | bahamarama | |
22/4/2024 21:49 | this is the kinda price i was hoping to buy at so i will in the morning. good luck everyone. | purple11 | |
12/4/2024 11:39 | By tempted back in below 1.4 | trying2trade | |
12/4/2024 09:59 | biodefence still rumbling. This issue may be on going so this gives Dr Sandler the opportunity to implement a alternative supplier ? | dreamtwister | |
10/4/2024 14:28 | Doing well innit | albert35911 | |
09/4/2024 15:19 | interesting link below, custom & off the shelf car-t manufacturing pro`s & cons ? hemogenyx have chosen to go down the custom route, | dreamtwister | |
08/4/2024 20:54 | FDA accepts Shorla’s oral liquid leukemia drug NDA SH-201 is an oral liquid drug, making the treatment accessible to patients who may struggle with taking tablets or other dosage forms. It slows or stops the growth of certain forms of leukemia, including chronic myeloid leukemia and acute lymphoblastic leukemia. The blood science is becoming more accessible & cost effective.... Below the link gives a insight to the Car-t science. | dreamtwister | |
08/4/2024 09:05 | well the cd38 therapy has been approved, Dr Sandler has now to bring cd19 to the clinical trials. | dreamtwister | |
07/4/2024 19:54 | hxxps://www.biospace Hemo next? bankruptcies skyrocket in biotech !! WHO OWNS HEMO CASINO SHARES !!? | marcus80 | |
07/4/2024 18:12 | Great news ! FDA allows expanded use of cell therapies for blood cancer The drugs from Johnson & Johnson and Bristol Myers Squibb can be used to treat patients in the earlier stages of a type of blood cancer. | dreamtwister | |
05/4/2024 11:53 | U.S. Application No. 17/133,448 Title: METHOD OF ELIMINATING HEMATOPOIETIC STEM CELLS/HEMATOPOIETIC PROGENITORS (HSC/HP) IN A PATIENT USING BI-SPECIFIC ANTIBODIES Applicant: HEMOGENYX LLC Inventor: Vladislav Sandler Issued as U.S. Patent No. 11,945,866 on April 2, 2024. | ashleyjv | |
05/4/2024 11:22 | End of year results due 28/29th | dreamtwister | |
05/4/2024 11:15 | Any reason why ? | john henry | |
05/4/2024 09:38 | i can for-see a Drug shortage leading to costs rising due to the USA V CHINA Biodefence Should congress pass the Legislation & it becomes Mandatory then i trust Dr Sandler has a plan B. " The Consumer is Not the Customer ! | dreamtwister | |
05/4/2024 09:13 | https://www.londonst | blackhorse23 | |
05/4/2024 08:30 | No it appears to be that ashleyjv is spot on as it is now April [and the last day of the current tax year with the new tax year starting on Monday] | apotheki |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions